FLT3-ITD is a constitutively activated variant of the FLT3 tyrosine kinase receptor that enhances cellular proliferation and reduces apoptosis of hematopoietic blasts, leading to relatively poor clinical outcome and a higher risk of relapse in AML [64–66]. This evidence concerns the gene FLT3 and acute myeloid leukemia.